Abstract
BackgroundRoutine surveillance on the therapeutic efficacy of artemisinin-based combination therapy (ACT) has been ongoing in Ghana since 2005. The sixth round of surveillance was conducted between 2015 and 2017 to determine the therapeutic efficacy of artesunate–amodiaquine (AS–AQ) and artemether–lumefantrine (AL) in 10 sentinel sites across the country.MethodsThe study was a one-arm, prospective, evaluation of the clinical, parasitological, and haematological responses to directly observed treatment with AS–AQ and AL among children 6 months to 9 years old with uncomplicated falciparum malaria. The WHO 2009 protocol on surveillance of anti-malaria drug efficacy was used for the study with primary outcomes as prevalence of day 3 parasitaemia and clinical and parasitological cure rates on day 28. Secondary outcomes assessed included patterns of fever and parasite clearance as well as changes in haemoglobin concentration.ResultsDay 3 parasitaemia was absent in all sites following treatment with AS–AQ whilst only one person (0.2%) was parasitaemic on day 3 following treatment with AL. Day 28 PCR-corrected cure rates following treatment with AS–AQ ranged between 96.7% (95% CI 88.5–99.6) and 100%, yielding a national rate of 99.2% (95% CI 97.7–99.7). Day 28 PCR-corrected cure rates following treatment with AL ranged between 91.3% (95% CI 79.2–97.6) and 100%, yielding a national rate of 96% (95% CI 93.5–97.6). Prevalence of fever declined by 88.4 and 80.4% after first day of treatment with AS–AQ and AL, respectively, whilst prevalence of parasitaemia on day 2 was 2.1% for AS–AQ and 1.5% for AL. Gametocytaemia was maintained at low levels (< 5%) during the 3 days of treatment. Post-treatment mean haemoglobin concentration was significantly higher than pre-treatment concentration following treatment with either AS–AQ or AL.ConclusionsThe therapeutic efficacy of AS–AQ and AL is over 90% in sentinel sites across Ghana. The two anti-malarial drugs therefore remain efficacious in the treatment of uncomplicated malaria in the country and continue to achieve rapid fever and parasite clearance as well as low gametocyte carriage rates and improved post-treatment mean haemoglobin concentration.
Highlights
Routine surveillance on the therapeutic efficacy of artemisinin-based combination therapy (ACT) has been ongoing in Ghana since 2005
This paper presents data on the therapeutic efficacy of AS–AQ and AL combinations from the sixth round of surveillance conducted between August 2015 and December 2017 in 10 sentinel sites across the country using the 2009 World Health Organization (WHO) protocol for surveillance of anti-malarial drug efficacy [15]
Mean weight ranged between 14.4 kg (± 5.3) in Wa regional Hospital (WRH) and 17.9 kg (± 6.0) in Navrongo War Memorial Hospital (NWMH), yielding an overall mean of 16.1 kg (± 5.5)
Summary
Routine surveillance on the therapeutic efficacy of artemisinin-based combination therapy (ACT) has been ongoing in Ghana since 2005. The sixth round of surveillance was conducted between 2015 and 2017 to deter‐ mine the therapeutic efficacy of artesunate–amodiaquine (AS–AQ) and artemether–lumefantrine (AL) in 10 sentinel sites across the country. Malaria control efforts in Ghana have, over the years, yielded some positive results. The proportion of out-patients suspected to have malaria decreased from 44% in 2013 to 34% in 2017 [3, 4]. Malaria parasite positivity rates among febrile cases in 30 sentinel sites have shown a significant decline from 23.7% in 2014 to 16.7% in 2017 (unpublished data). Despite the gains made in control efforts, malaria remains a major public health problem in Ghana accounting for an annual economic loss of approximately US$6.6 million among businesses in the country [6]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have